

22 July 2021

217-MDD-302 Study Results Posting

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of SAGE-217 with a Fixed, Repeated Treatment Regimen on Relapse Prevention in Adults with Major Depressive Disorder

EudraCT Number: 2019-002640-25

Sponsor's Protocol Number: 217-MDD-302

Trial Status: Prematurely Ended

Reason for Premature Termination: Clinical Study 217-MDD-302 (2019-002640-25) was terminated before enrollment of subjects in the European Union, as per the sponsor's discretion. Therefore, results are not posted for this study. There have been no safety concerns that led to the study closure.